Cure fractions among TT patients only
| . | n . | Median follow-up time (IQR), y . | PFS cure fraction, % . |
|---|---|---|---|
| All TT patients | 1802 | 10.8 (7.5-14.3) | 16.4 |
| Year of first transplant | |||
| <1997 | 192 | 22.0 (19.5-24.5) | 6.3 |
| 1998-2003 | 496 | 15.0 (12.8-16.7) | 17.3 |
| 2004-2008 | 549 | 11.0 (9.7-13.0) | 20.0 |
| 2009-2013 | 455 | 6.8 (5.7-8.2) | 31.3 |
| ≥2014 | 110 | 3.1 (2.3-3.9) | 0.0 |
| Age, y | |||
| <65 | 1360 | 11.0 (7.7-14.6) | 19.8 |
| ≥65 | 442 | 9.9 (6.6-13.2) | 3.0 |
| Sex | |||
| Female | 710 | 10.9 (7.6-14.6) | 22.9 |
| Male | 1092 | 10.8 (7.4-14.3) | 12.4 |
| GEP70 | |||
| Low risk | 1092 | 9.6 (6.9-12.8) | 23.1 |
| High risk | 184 | 8.9 (6.8-12.2) | 9.0 |
| Any chromosomal abnormality | |||
| No | 1104 | 11.5 (8.0-14.7) | 14.0 |
| Yes | 692 | 9.8 (6.6-13.5) | 18.6 |
| TC6 classification | |||
| CCND1 | 239 | 8.9 (6.0-11.2) | 31.9 |
| CCND3 | 22 | 8.9 (6.4-10.9) | 56.3 |
| D1 | 392 | 838 (6.6-11.9) | 24.4 |
| D2 | 328 | 9.5 (6.6-12.8) | 14.1 |
| MAF/MAFB | 65 | 9.8 (6.5-12.1) | 13.5 |
| MMSET | 158 | 8.5 (6.8-11.2) | 26.2 |
| . | n . | Median follow-up time (IQR), y . | PFS cure fraction, % . |
|---|---|---|---|
| All TT patients | 1802 | 10.8 (7.5-14.3) | 16.4 |
| Year of first transplant | |||
| <1997 | 192 | 22.0 (19.5-24.5) | 6.3 |
| 1998-2003 | 496 | 15.0 (12.8-16.7) | 17.3 |
| 2004-2008 | 549 | 11.0 (9.7-13.0) | 20.0 |
| 2009-2013 | 455 | 6.8 (5.7-8.2) | 31.3 |
| ≥2014 | 110 | 3.1 (2.3-3.9) | 0.0 |
| Age, y | |||
| <65 | 1360 | 11.0 (7.7-14.6) | 19.8 |
| ≥65 | 442 | 9.9 (6.6-13.2) | 3.0 |
| Sex | |||
| Female | 710 | 10.9 (7.6-14.6) | 22.9 |
| Male | 1092 | 10.8 (7.4-14.3) | 12.4 |
| GEP70 | |||
| Low risk | 1092 | 9.6 (6.9-12.8) | 23.1 |
| High risk | 184 | 8.9 (6.8-12.2) | 9.0 |
| Any chromosomal abnormality | |||
| No | 1104 | 11.5 (8.0-14.7) | 14.0 |
| Yes | 692 | 9.8 (6.6-13.5) | 18.6 |
| TC6 classification | |||
| CCND1 | 239 | 8.9 (6.0-11.2) | 31.9 |
| CCND3 | 22 | 8.9 (6.4-10.9) | 56.3 |
| D1 | 392 | 838 (6.6-11.9) | 24.4 |
| D2 | 328 | 9.5 (6.6-12.8) | 14.1 |
| MAF/MAFB | 65 | 9.8 (6.5-12.1) | 13.5 |
| MMSET | 158 | 8.5 (6.8-11.2) | 26.2 |
The cure fraction is the estimated percent of long-term survivors without MM progression or relapse.
IQR, interquartile range.